Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 4 | 2017 | 165 | 1.120 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 27 | 1.120 |
Why?
|
| Palliative Care | 5 | 2020 | 58 | 1.110 |
Why?
|
| Goals | 1 | 2020 | 33 | 0.730 |
Why?
|
| Estrogens | 4 | 2013 | 73 | 0.650 |
Why?
|
| Bone Density | 6 | 2014 | 96 | 0.640 |
Why?
|
| Body Composition | 12 | 2016 | 82 | 0.600 |
Why?
|
| Organizational Objectives | 1 | 2017 | 19 | 0.590 |
Why?
|
| Program Development | 1 | 2017 | 81 | 0.570 |
Why?
|
| Homosexuality | 1 | 2016 | 5 | 0.560 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 63 | 0.560 |
Why?
|
| Aged | 22 | 2020 | 6417 | 0.560 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 4 | 0.520 |
Why?
|
| Medication Therapy Management | 1 | 2015 | 6 | 0.520 |
Why?
|
| Health Status Disparities | 1 | 2017 | 153 | 0.520 |
Why?
|
| Homosexuality, Female | 1 | 2014 | 8 | 0.480 |
Why?
|
| Cultural Competency | 1 | 2014 | 14 | 0.470 |
Why?
|
| Bisexuality | 1 | 2014 | 12 | 0.470 |
Why?
|
| Social Work | 1 | 2014 | 13 | 0.470 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 38 | 0.470 |
Why?
|
| Obesity | 8 | 2016 | 855 | 0.460 |
Why?
|
| Transgender Persons | 1 | 2014 | 38 | 0.460 |
Why?
|
| Humans | 38 | 2020 | 18430 | 0.440 |
Why?
|
| Female | 33 | 2019 | 13136 | 0.430 |
Why?
|
| Weight Loss | 5 | 2016 | 321 | 0.430 |
Why?
|
| Exercise | 7 | 2014 | 495 | 0.410 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 382 | 0.400 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2013 | 104 | 0.390 |
Why?
|
| Middle Aged | 24 | 2017 | 8284 | 0.380 |
Why?
|
| Postmenopause | 7 | 2014 | 267 | 0.370 |
Why?
|
| Raloxifene Hydrochloride | 2 | 2013 | 13 | 0.360 |
Why?
|
| Male | 20 | 2019 | 10440 | 0.360 |
Why?
|
| Saliva | 2 | 2005 | 12 | 0.320 |
Why?
|
| Muscle, Skeletal | 4 | 2012 | 32 | 0.320 |
Why?
|
| Social Workers | 2 | 2020 | 2 | 0.320 |
Why?
|
| Insulin | 7 | 2013 | 208 | 0.300 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 2003 | 0.280 |
Why?
|
| Adiposity | 3 | 2013 | 67 | 0.280 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 4 | 0.260 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 4 | 0.260 |
Why?
|
| Hydrocortisone | 1 | 2005 | 16 | 0.260 |
Why?
|
| Interviews as Topic | 2 | 2017 | 327 | 0.250 |
Why?
|
| Physical Endurance | 1 | 2003 | 5 | 0.230 |
Why?
|
| Hypogonadism | 1 | 2003 | 4 | 0.230 |
Why?
|
| Bone and Bones | 2 | 2014 | 9 | 0.230 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2013 | 5 | 0.210 |
Why?
|
| Colorado | 4 | 2019 | 211 | 0.210 |
Why?
|
| Blood Glucose | 5 | 2013 | 346 | 0.200 |
Why?
|
| Adult | 12 | 2016 | 7910 | 0.190 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 13 | 0.190 |
Why?
|
| Insulin Resistance | 2 | 2013 | 129 | 0.190 |
Why?
|
| Lipolysis | 2 | 2013 | 2 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2020 | 120 | 0.180 |
Why?
|
| Needs Assessment | 2 | 2014 | 69 | 0.180 |
Why?
|
| Caregivers | 1 | 2020 | 126 | 0.170 |
Why?
|
| Dehydroepiandrosterone | 2 | 2011 | 5 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 54 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 77 | 0.160 |
Why?
|
| Subcutaneous Fat | 2 | 2010 | 3 | 0.160 |
Why?
|
| Glycerol | 4 | 2013 | 4 | 0.160 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 12 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2018 | 12 | 0.160 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2011 | 11 | 0.160 |
Why?
|
| Patient Navigation | 1 | 2018 | 17 | 0.160 |
Why?
|
| Social Support | 2 | 2018 | 214 | 0.160 |
Why?
|
| Patient Admission | 3 | 2015 | 76 | 0.160 |
Why?
|
| Ageism | 1 | 2016 | 2 | 0.140 |
Why?
|
| Caloric Restriction | 1 | 2016 | 6 | 0.140 |
Why?
|
| Energy Metabolism | 3 | 2013 | 50 | 0.140 |
Why?
|
| Independent Living | 1 | 2016 | 21 | 0.140 |
Why?
|
| Fasting | 1 | 2016 | 48 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2019 | 468 | 0.140 |
Why?
|
| Housing | 1 | 2016 | 40 | 0.140 |
Why?
|
| Focus Groups | 1 | 2016 | 154 | 0.130 |
Why?
|
| Hispanic Americans | 1 | 2018 | 428 | 0.130 |
Why?
|
| Health Personnel | 1 | 2017 | 126 | 0.130 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 8 | 0.130 |
Why?
|
| Qualitative Research | 1 | 2016 | 272 | 0.130 |
Why?
|
| Body Weight | 3 | 2016 | 223 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 109 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2016 | 256 | 0.120 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2013 | 12 | 0.120 |
Why?
|
| Glucose | 2 | 2011 | 30 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2014 | 74 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2013 | 32 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2012 | 4 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 4 | 0.110 |
Why?
|
| Resistance Training | 1 | 2012 | 8 | 0.110 |
Why?
|
| Thigh | 2 | 2010 | 11 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 188 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 444 | 0.100 |
Why?
|
| Cognition | 1 | 2013 | 82 | 0.100 |
Why?
|
| Receptors, CCR5 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2012 | 5 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 13 | 0.100 |
Why?
|
| Thinness | 1 | 2012 | 29 | 0.100 |
Why?
|
| HIV-1 | 1 | 2012 | 71 | 0.100 |
Why?
|
| Absorptiometry, Photon | 4 | 2014 | 52 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2012 | 92 | 0.100 |
Why?
|
| Hormone Antagonists | 1 | 2011 | 1 | 0.100 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 3 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 2 | 2008 | 28 | 0.100 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 44 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 476 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 15 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2015 | 2550 | 0.090 |
Why?
|
| Weight Gain | 1 | 2011 | 181 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2010 | 65 | 0.090 |
Why?
|
| Biomarkers | 4 | 2012 | 308 | 0.090 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 38 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2008 | 14 | 0.080 |
Why?
|
| Motor Activity | 1 | 2008 | 215 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 33 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2006 | 71 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2005 | 1 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 5 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2005 | 13 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 20 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2005 | 11 | 0.070 |
Why?
|
| Health Status | 1 | 2008 | 328 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2005 | 21 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2013 | 34 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 45 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2005 | 8 | 0.060 |
Why?
|
| Basal Metabolism | 1 | 2005 | 5 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 695 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2005 | 60 | 0.060 |
Why?
|
| Radioisotope Dilution Technique | 1 | 2004 | 1 | 0.060 |
Why?
|
| Deuterium | 1 | 2004 | 3 | 0.060 |
Why?
|
| Body Water | 1 | 2004 | 3 | 0.060 |
Why?
|
| Serum | 1 | 2004 | 3 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 321 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2016 | 237 | 0.060 |
Why?
|
| Glucose Clamp Technique | 3 | 2013 | 13 | 0.060 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2004 | 12 | 0.060 |
Why?
|
| Hypoventilation | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 8 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 20 | 0.060 |
Why?
|
| Terminal Care | 1 | 2003 | 36 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 54 | 0.050 |
Why?
|
| Length of Stay | 1 | 2004 | 183 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2003 | 50 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 1389 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 7 | 0.050 |
Why?
|
| Lipids | 2 | 2013 | 78 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2012 | 6 | 0.050 |
Why?
|
| Peptides | 2 | 2012 | 12 | 0.050 |
Why?
|
| Weight Reduction Programs | 2 | 2014 | 60 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2004 | 120 | 0.050 |
Why?
|
| Energy Intake | 2 | 2016 | 103 | 0.050 |
Why?
|
| Triglycerides | 2 | 2012 | 87 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2016 | 1296 | 0.050 |
Why?
|
| Calorimetry | 2 | 2012 | 2 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 208 | 0.050 |
Why?
|
| Fatty Acids | 2 | 2012 | 8 | 0.050 |
Why?
|
| Linear Models | 3 | 2008 | 243 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 288 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 392 | 0.040 |
Why?
|
| Diet | 3 | 2009 | 371 | 0.040 |
Why?
|
| Hip | 2 | 2011 | 9 | 0.040 |
Why?
|
| Placebos | 2 | 2011 | 23 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2011 | 974 | 0.040 |
Why?
|
| Lumbar Vertebrae | 2 | 2011 | 21 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 630 | 0.040 |
Why?
|
| Glucose Tolerance Test | 2 | 2013 | 106 | 0.040 |
Why?
|
| Kinetics | 2 | 2012 | 12 | 0.040 |
Why?
|
| Heart Failure | 1 | 2003 | 398 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2008 | 165 | 0.040 |
Why?
|
| Streptococcus agalactiae | 1 | 1997 | 8 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 342 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 1997 | 22 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 1360 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2016 | 27 | 0.030 |
Why?
|
| Physical Fitness | 2 | 2008 | 76 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 10 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1997 | 271 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 365 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 1269 | 0.030 |
Why?
|
| Femur Neck | 1 | 2014 | 6 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 22 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2013 | 3 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2012 | 2 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 7 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 93 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 2 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 51 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2012 | 4 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 5 | 0.030 |
Why?
|
| DNA | 1 | 2012 | 25 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 46 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2012 | 5 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 53 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 23 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 2011 | 5 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2011 | 2 | 0.020 |
Why?
|
| Oxytocics | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 112 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 80 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 33 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 40 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 125 | 0.020 |
Why?
|
| Risk Factors | 2 | 2010 | 3449 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 10 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2009 | 22 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1173 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 167 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 310 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 17 | 0.020 |
Why?
|
| Testosterone | 1 | 2008 | 22 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 965 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 198 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 661 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 319 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Microdialysis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 45 | 0.020 |
Why?
|
| Femur | 1 | 2006 | 10 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2006 | 28 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1136 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2006 | 70 | 0.020 |
Why?
|
| Buttocks | 1 | 2005 | 1 | 0.020 |
Why?
|
| Vitamin D | 1 | 2006 | 80 | 0.020 |
Why?
|
| Abdomen | 1 | 2005 | 21 | 0.020 |
Why?
|
| Luteal Phase | 1 | 2005 | 1 | 0.020 |
Why?
|
| Follicular Phase | 1 | 2005 | 2 | 0.020 |
Why?
|
| Premenopause | 1 | 2005 | 27 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 399 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 2518 | 0.020 |
Why?
|
| Rest | 1 | 2004 | 3 | 0.010 |
Why?
|
| C-Peptide | 1 | 2004 | 6 | 0.010 |
Why?
|
| Bicarbonates | 1 | 2004 | 2 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2004 | 2 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 33 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 22 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2004 | 17 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2003 | 5 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2003 | 9 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 124 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 253 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 226 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 24 | 0.010 |
Why?
|
| Critical Care | 1 | 2004 | 73 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 160 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 108 | 0.010 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2004 | 254 | 0.010 |
Why?
|
| Physicians | 1 | 2003 | 141 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 619 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 743 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 690 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 2672 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 760 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 3798 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1997 | 872 | 0.010 |
Why?
|
Concepts
(256)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->